American Journal of Nephrology

Patient-Oriented, Translational Research: Research Article

Torres J.a· Ennis J.L.b· Chapman A.B.c· McGill R.L.c

Author affiliations

aHarold Washington College, Chicago, IL, USA
bLaboratory Corporation of America, Chicago, IL, USA
cSection of Nephrology, University of Chicago, Chicago, IL, USA

Log in to MyKarger to check if you already have access to this content.

Buy FullText & PDF Unlimited re-access via MyKarger Unrestricted printing, no saving restrictions for personal use read more

CHF 38.00 *
EUR 35.00 *
USD 39.00 *

Select

KAB

Buy a Karger Article Bundle (KAB) and profit from a discount!

If you would like to redeem your KAB credit, please log in.

Save over 20% compared to the individual article price.

Learn more

Access via DeepDyve Unlimited fulltext viewing of this article Organize, annotate and mark up articles Printing and downloading restrictions apply

Select

Subscribe Access to all articles of the subscribed year(s) guaranteed for 5 years Unlimited re-access via Subscriber Login or MyKarger Unrestricted printing, no saving restrictions for personal use read more

Subcription rates

Select

* The final prices may differ from the prices shown due to specifics of VAT rules.

Article / Publication Details

First-Page Preview

Received: September 22, 2021
Accepted: April 29, 2022
Published online: June 23, 2022

Number of Print Pages: 8
Number of Figures: 3
Number of Tables: 3

ISSN: 0250-8095 (Print)
eISSN: 1421-9670 (Online)

For additional information: https://www.karger.com/AJN

Abstract

Introduction: Serum creatinine is the traditional biomarker for estimating glomerular filtration rate (eGFR). Cystatin C is an alternative biomarker for which estimating equations exist. The use of cystatin C testing, and the interrelationships among the recently revised Chronic Kidney Disease Epidemiology (CKD-EPI) 2021 estimating equations, was evaluated in a national outpatient laboratory dataset. Methods: Cystatin C results reported on adults between November 2011 and June 2018 by Laboratory Corporation of America Holdings were examined, with classification of ordering providers and diagnostic codes. Updated eGFR results were calculated using the CKD-EPI 2021 equations for each sample with both cystatin C and creatinine values available. The Spearman correlation coefficients were calculated. Reclassification at clinically relevant cut-off values was examined. Results: There were 87,803 serum cystatin C levels among 55,360 patients; mean age 58 ± 17 years; 50% women. Cystatin C usage increased over time and was ordered for many indications. Among 73,367 samples with simultaneous creatinine and cystatin C, r = 0.84 between eGFR-creatinine and eGFR-cystatin. Correlations of eGFR-creatinine, eGFR-cystatin, and the averaged result of the two equations to the new combined equation were r = 0.94, r = 0.97, and r = 0.998, respectively (p < 0.001 for all). Use of combined/averaged equations tended to result in a higher eGFR and upclassification, compared to eGFR-creatinine. Conclusion/Discussion: Use of Cystatin C is increasing and has moved beyond the nephrology community and the original indications from the 2012 KDIGO guidelines. Community utilization of cystatin C measurement is likely to expand, and understanding of the relationships between estimating equations will help clinicians optimize their use in the outpatient setting.

© 2022 S. Karger AG, Basel

References Centers for Disease Control and Prevention. Chronic kidney disease in the United States, 2021. Atlanta, GA: US Department of Health and Human Services, Centers for Disease Control and Prevention; 2021. Chu CD, McCulloch CE, Banerjee T, Pavkov ME, Burrows NR, Gillespie BW, et al. Centers for disease control and prevention chronic kidney disease surveillance team. CKD awareness among US adults by future risk of kidney failure. Am J Kidney Dis. 2020;76(2):174–83. Vart P, Grams ME. Measuring and assessing kidney function. Semin Nephrol. 2016;36(4):262–72. Peake M, Whiting M. Measurement of serum creatinine: current status and future goals. Clin Biochem Rev. 2006;27(4):173–84. Schmidt RL, Straseski JA, Raphael KL, Adams AH, Lehman CM. A risk assessment of the Jaffe vs enzymatic method for creatinine measurement in an outpatient population. PLoS One. 2015;10(11):e0143205. Inker LA, Schmid CH, Tighiouart H, Eckfeldt JH, Feldman HI, Greene T, et al. Estimating glomerular filtration rate from serum creatinine and cystatin C. New Engl J Med. 2012;367(1):20–9. Levey AS, Inker LA. Assessment of glomerular filtration rate in health and disease: a state of the art review. Clin Pharmacol Ther. 2017;102(3):405–19. Filler G, Bökenkamp A, Hofmann W, Bricon TL, Martínez-Bru C, Grubb A. Cystatin C as a marker of GFR: history, indications, and future research. Clin Biochem. 2004;38(1):1–8. Chew JS, Saleem M, Florkowski CM, George PM. Cystatin C: a paradigm of evidence based laboratory medicine. Clin Biochem Rev. 2008;29(2):47–62. Benoit SV, Kathman T, Patel J, Stegman M, Cobb C, Hoehn J, et al. GFR estimation after cystatin C reference material change. Kidney Int Rep. 2020;6(2):429–36. Kidney Disease: Improving Global Outcome (KDIGO) Work Group. KDIGO 2012 clinical practice guideline for the evaluation and management of chronic kidney disease. Kidney Int Suppl. 2013;3:1–50. Inker LA, Eneanya ND, Coresh J, Tighiouart H, Wang D, Sang Y, et al. New creatinine-and cystatin-C based equations to estimate GFR without race. N Engl J Med. 2021;385(19):1737–49. Powe NR. Black kidney function matters. Use or misuse of race? JAMA. 2020;324(8):737–8. Levey AS, Becker C, Inker LA. Glomerular filtration rate and albuminuria for detection and staging of acute and chronic kidney disease in adults: a systematic review. JAMA. 2015;313(8):837–46. Erstad BL, Nix DE. Assessment of kidney function in patients with extreme obesity: a narrative review. Ann Pharmacother. 2021;55(1):80–8. Piano S, Brocca A, Angeli P. Renal function in cirrhosis: a critical review of available tools. Semin Liver Dis. 2018;38(3):230–41. Allegretti AS, Solà E, Ginès P. Clinical application of kidney biomarkers in cirrhosis. Am J Kidney Dis. 2020;76(5):710–9. Peralta CA, Shlipak MG, Judd S, Cushman M, McClellan W, Zakai NA, et al. Detection of chronic kidney disease with creatinine, cystatin C, and urine albumin-to-creatinine ratio and association with progression to end-stage renal disease and mortality. JAMA. 2011;305(15):1545–52. Chen LX, Koyner JL. Biomarkers in acute kidney injury. Crit Care Clin. 2015;31(4):633–48. Ho FK, Celis-Morales CA, Gray SR, Katikireddi SV, Niedzwiedz CL, Hastie C, et al. Modifiable and non-modifiable risk factors for Covid-19, and comparison to risk factors for influenza and pneumonia: results from a UK Biobank prospective cohort study. BMJ Open. 2020;10:e040402. Casado JL, Monsalvo M, Vizcarra P, Fontecha M, Serrano-Villar S, Moreno S. Evaluation of kidney function in HIV-infected patients receiving an antiretroviral regimen containing one or two inhibitors of the tubular secretion of creatinine. HIV Med. 2019;20(10):648–56. Peralta CA, Katz R, Sarnak MJ, Ix J, Fried LF, De Boer I, et al. Cystatin C identifies chronic kidney disease patients at higher risk for complications. J Am Soc Nephrol. 2011;22:147–55. Muslimovic A, Tulumovic D, Hasanspahic S, Hamzic-Mehmedbasic A, Temimovi R. Serum cystatin C: marker of inflammation and cardiovascular morbidity in chronic kidney disease stages 1–4. Mater Sociomed. 2015;27(2):75–8. Chen A, Zhang J, Feng J, Zhou G, Jin X, Pan J. Higher serum level of cystatin C: an additional risk factor of CAD. Medicine. 2021;100(2):e24269. Tummalapalli SL, Shlipak MG, Damster S, Jha V, Malik C, Levin A, et al. Availability and affordability of kidney health laboratory tests around the globe. Am J Nephrol. 2020;51:959–65. Article / Publication Details

First-Page Preview

Received: September 22, 2021
Accepted: April 29, 2022
Published online: June 23, 2022

Number of Print Pages: 8
Number of Figures: 3
Number of Tables: 3

ISSN: 0250-8095 (Print)
eISSN: 1421-9670 (Online)

For additional information: https://www.karger.com/AJN

Copyright / Drug Dosage / Disclaimer Copyright: All rights reserved. No part of this publication may be translated into other languages, reproduced or utilized in any form or by any means, electronic or mechanical, including photocopying, recording, microcopying, or by any information storage and retrieval system, without permission in writing from the publisher.
Drug Dosage: The authors and the publisher have exerted every effort to ensure that drug selection and dosage set forth in this text are in accord with current recommendations and practice at the time of publication. However, in view of ongoing research, changes in government regulations, and the constant flow of information relating to drug therapy and drug reactions, the reader is urged to check the package insert for each drug for any changes in indications and dosage and for added warnings and precautions. This is particularly important when the recommended agent is a new and/or infrequently employed drug.
Disclaimer: The statements, opinions and data contained in this publication are solely those of the individual authors and contributors and not of the publishers and the editor(s). The appearance of advertisements or/and product references in the publication is not a warranty, endorsement, or approval of the products or services advertised or of their effectiveness, quality or safety. The publisher and the editor(s) disclaim responsibility for any injury to persons or property resulting from any ideas, methods, instructions or products referred to in the content or advertisements.